Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment
Liraglutide has been extensively applied in the treatment of type 2 diabetes mellitus (T2DM), but its 11–15 h half-life resulted in daily administration, which led to poor patient compliance. This study aimed to solve this problem by developing liraglutide-loaded microspheres with a 1 month sustaine...
Gespeichert in:
Veröffentlicht in: | ACS applied materials & interfaces 2024-05, Vol.16 (20), p.25869-25878 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!